Background {#Sec1}
==========

A high level of anti-citrullinated protein antibodies (ACPA) is predictive of radiographic progression in rheumatoid arthritis (RA) \[[@CR1], [@CR2]\], and ACPA positivity has been associated with radiographic damage even before RA onset \[[@CR1]\] and in early RA \[[@CR1], [@CR3]--[@CR7]\]. Positivity to the anti-cyclic citrullinated peptide (anti-CCP2) test, hereafter referred to as "anti-CCP", reflects presence of antibodies to mixed cyclic citrullinated peptides (i.e. ACPAs) as an artificial mimic of the true autoantigens \[[@CR8]\]. The ACPA response against citrullinated antigens in RA, hereafter referred to as "ACPA reactivity", has been shown to be heterogeneous \[[@CR9]--[@CR15]\]. Presence of ACPA reactivities may precede the onset of anti-CCP positivity \[[@CR16]\], as several studies have shown that both the number of ACPA reactivities and their individual titres increase before clinical onset of RA \[[@CR12], [@CR13], [@CR16]--[@CR19]\].

RA patients may be characterised by distinct autoantibody profiles, as serum samples from the majority of anti-CCP-positive patients react with one or more specific citrullinated target proteins \[[@CR12], [@CR13], [@CR16], [@CR17], [@CR20]\]. ACPA reactivities have also been found in patients who are anti-CCP negative \[[@CR14], [@CR15], [@CR20]--[@CR22]\]. Previous studies have shown that the individual titre of selected ACPA reactivities, such as anti-citrullinated vimentin, declines significantly after initiation of disease-modifying antirheumatic drug (DMARD) treatment, while the presence of anti-CCP antibodies remains stable over time \[[@CR23], [@CR24]\]. Higher numbers of specificities have been associated with increased risk of relapse in patients with early RA, who are in clinical remission and tapering DMARDs \[[@CR25]\].

ACPA reactivity against citrullinated vimentin has been proposed to be involved in the bone-destructive processes in undifferentiated arthritis \[[@CR26]\], early RA \[[@CR23], [@CR24], [@CR26], [@CR27]\] and established RA \[[@CR28]\]. In early RA, seroreversion of citrullinated vimentin during the first 3 months of treatment has been shown to be associated with significantly less 2-year radiographic progression, compared with patients who remained positive \[[@CR23]\]. However, the clinical relevance of measuring ACPA reactivities to obtain prognostic information on treatment response or radiographic damage in early undifferentiated arthritis \[[@CR22], [@CR29]--[@CR31]\] or early RA \[[@CR32]\] has not been established.

To our knowledge, the associations between individual ACPA reactivities and disease characteristics have not been studied in patients with early RA classified according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria. The aim of this study was to assess the prevalence of selected baseline ACPA reactivities, and to investigate the association between ACPA reactivities and disease activity, ultrasound findings, treatment response and radiographic damage in an inception cohort of patients with early RA.

Methods {#Sec2}
=======

Design and setting of the study {#Sec3}
-------------------------------

We used data from the completed "Aiming for remission in rheumatoid arthritis: a randomized trial examining the benefit of ultrasound in a clinical tight control regimen" (the ARCTIC trial, NCT01205854) \[[@CR33]\], a study designed to assess whether incorporation of ultrasound information into treatment decisions would lead to improved patient outcomes. All patients were treated according to a tight-control treat-to-target strategy, with evaluation at baseline and 12 additional study visits during the 2-year follow up. The treatment target was no swollen joints and Disease Activity Score (DAS) \< 1.6 \[[@CR34]\], and in half of the patients an additional target was no joints with disease activity demonstrated on power Doppler ultrasound \[[@CR33]\]. Core disease activity measures were collected at each visit. Initial treatment consisted of methotrexate monotherapy 15 mg/week escalating to 20 mg/week and prednisolone starting at 15 mg with tapering to stop over 7 weeks. If the treatment target was not achieved, treatment was intensified following a predetermined treatment protocol, with escalation to triple therapy and then biologic DMARDs (bDMARDs). Swollen joints and/or joints with power Doppler ultrasound activity could be injected with triamcinolone hexacetonide (up to a maximum of 80 mg per visit). As clinical and radiographic outcomes of the two strategy arms were similar after 2 years, in the current report the data from the two arms were pooled and analysed together.

Patients and controls {#Sec4}
---------------------

In the ARCTIC trial \[[@CR33]\], 230 DMARD-naïve patients with early RA classified according to the 2010 ACR/EULAR criteria were recruited at 11 Norwegian rheumatology centres between September 2010 and April 2013. The patients were 18--75 years of age with symptom duration less than 2 years from first patient-reported swollen joint, and DMARD-naïve with indication for DMARD treatment. For the current analyses, all patients with follow-up biobank serum samples were selected (*n* = 217). Controls were blood donors with similar characteristics to the patients included in the study (age, gender and smoking status (*n* = 94)). Serum samples were collected at each visit and stored at - 70 °C. The study was approved by the local ethics committee of the South-Eastern Norway Regional Health Authority and was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent.

Laboratory examinations {#Sec5}
-----------------------

Analysis of 16 ACPA reactivities and the corresponding native arginine-containing control peptides targeting citrullinated peptides from fibrinogen (Fib), alpha-1 enolase (citrullinated enolase peptide 1 (CEP-1)), vimentin (Vim), filaggrin (Fil) and histone (H) was performed using a multiplex chip-based assay based on the ImmunoCAP ISAC system (Phadia AB, Uppsala, Sweden) \[[@CR15], [@CR20]\]. All samples from 0, 3, 12 and 24 months were analysed. ACPA reactivity titres (AU/ml) were considered positive if above the 98-percentile of values in 619 subjects without RA \[[@CR20]\]. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were analysed locally by in-house standard methodology. Anti-CCP was analysed by fluorometric enzyme immunocapture assay (FEIA) (positive if ≥ 10 IU/mL) and rheumatoid factor (RF) by ELISA (positive if ≥ 25 IU/mL).

Clinical and imaging assessments {#Sec6}
--------------------------------

Clinical joint examination was performed using the 44 swollen joint count (SJC44) and Ritchie Articular Index for tender joints \[[@CR35]\]. Patients and physicians reported the overall assessment of disease activity and pain on visual analogue scales (VAS), range 0--100. The composite index DAS was calculated \[[@CR34]\] and response according to the EULAR criteria \[[@CR36]\] and fulfillment of ACR/EULAR Boolean remission criteria were evaluated \[[@CR37]\].

Radiographic examinations of the hands and feet from baseline, 12 and 24 months were scored according to the van der Heijde modified Sharp score \[[@CR38]\]. Scoring was performed in chronological order by two trained readers blinded to clinical information, and the average of the two scores was used. Presence of erosive disease was defined as van der Heijde modified Sharp erosion score ≥ 3, in line with the definition suggested by a EULAR task force \[[@CR39]\]. Radiographic progression was defined as a change in van der Heijde modified Sharp total score of ≥ 2 units over 2 years, which is above the smallest detectable change (1.94 units).

Ultrasound examination was performed according to a validated semi-quantitative 32-joint protocol with scores of 0--3, separately for grey scale synovitis and power Doppler ultrasound \[[@CR40]\]. Half the patients underwent ultrasound examination at all visits, while the patients in the conventional group were examined clinically at every visit and by ultrasound at baseline, 12 and 24 months \[[@CR33]\]. Examiners were thoroughly trained and an atlas was available for reference \[[@CR40]\].

Statistical analysis {#Sec7}
--------------------

Baseline characteristics were compared using the chi-square test, *t* test and Mann-Whitney U test, as appropriate. Correlation between anti-CCP/ACPA reactivity levels and number of ACPA reactivities and disease activity measures, ultrasound and radiography scores were assessed using Spearman's rank correlation coefficient. Spearman's correlation was classified as very weak, weak, moderate, strong or very strong \[[@CR41]\]. Association between number of ACPA reactivities and treatment response was evaluated using the Mann-Whitney U test. Association between anti-CCP/ACPA reactivity status and continuous variables was evaluated by the Mann-Whitney U test, and association with categorical variables was assessed by the chi-square test. ACPA reactivity median levels at baseline and follow-up visits were compared by paired samples using the Wilcox test, comparing each time point with the baseline level. A *p* value \<0.05 was considered statistically significant. Statistical analyses were performed using Stata Statistical Software, version 14 (StataCorp LLC, TX, USA) and R Statistical Software, version 3.4.0 (copyright 2017, The R Foundation for Statistical Computing).

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

A total of 217 patients and 94 healthy controls were included in the study. Baseline characteristics according to autoantibody subgroups are provided in Table [1](#Tab1){ref-type="table"}. Presence of ACPA reactivities was seen mainly in patients positive for anti-CCP and RF (Table [1](#Tab1){ref-type="table"}), but ACPA reactivities also occurred more frequently in anti-CCP/RF negative patients than in controls (0 (0, 1) vs. 0 (0, 0), *p* = 0.050; Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). The anti-CCP level significantly correlated with the number of citrullinated antigens recognised (*r* = 0.76, *p* \< 0.0001). ACPA reactivity presence in the RF-negative subset was generally higher than in the anti-CCP-negative group (Table [1](#Tab1){ref-type="table"}). Among the 63 RF-negative patients, 31 were anti-CCP positive.Table 1Baseline characteristics and anti-citrullinated protein antibody (ACPA) reactivities in subgroups of patients with rheumatoid arthritis (RA) and controlsAll RA\
*n* = 217Anti-CCP+\
*n* = 178Anti-CCP-\
*n* = 39RF+\
*n* = 154RF-\
*n* = 63Anti-CCP+/RF+\
*n* = 147Anti-CCP-/RF-\
*n* = 32Controls\
*n* = 94Age, years^a^51.5 (13.6)50.8 (13.2)55.0 (14.9)51.9 (13.3)50.8 (14.2)51.7 (13.6)55.0 (16.1)52.1 (9.2)Female^b^131 (60)109 (61)22 (56)91 (59)40 (63)86 (59)17 (53)57 (61)Ever-smoker^b^148 (68)122 (69)26 (67)109 (71)39 (62)103 (70)20 (62)60 (64)DAS^a^3.5 (1.2)3.4 (1.1)4.0 (1.3)3.5 (1.2)3.5 (1.2)3.42 (1.1)3.9 (1.2)NADAS28^a^4.4 (1.2)4.4 (1.2)4.7 (1.2)4.5 (1.2)4.2 (1.3)4.5 (1.1)4.5 (1.1)NAvdHSS total^c^4.0 \[1.5, 8.0\]4.0 \[1.5, 7.9\]4.5 \[2.0, 10\]4.5 \[2.0, 8.0\]3.5 \[1.5, 10\]4.5 \[2.0, 8.0\]5.5 \[1.8, 12.8\]NAvdHSS erosion^c^3.0 \[1, 4.5\]3.0 \[1, 4.5\]3.0 \[1.0, 5.5\]3.0 \[1.5, 4.5\]3.0 \[1.0, 5.5\]3.0 \[1.0, 4.5\]3.0 \[1.0, 6.3\]NAvdHSS JSN^c^1.0 \[0.0, 3.0\]1.0 \[0.0, 3.0\]1.5 \[0.0, 5.0\]1.0 \[0.0, 3.0\]1.0 \[0.0, 3.0\]1.0 \[0.0, 3.0\]1.5 \[0.0, 6.5\]NAUltrasound grey scale^c^18 \[10, 28\]16 \[9, 24\]33 \[20, 51\]17 \[10, 26\]21 \[12, 36\]16 \[9, 25\]33 \[21, 52\]NAUltrasound power Doppler^c^7 \[3, 14\]6 \[2, 12\]14 \[6, 28\]6 \[2, 13\]8 \[3, 15\]6 \[2, 12\]13 \[6, 29\]NANumber of ACPA reactivities^c^9 \[4, 12\]10 \[7, 12\]0 \[0, 1\]10 \[7, 12\]2 \[0, 10\]10 \[7, 12\]0 \[0, 1\]0 \[0, 0\]ACPA reactivity status, *n* (%) Fibβ 60-74cit162 (75)160 (90)2 (5)136 (88)26 (41)134 (91)0 (0)0 (0) Vim 60-75cit159 (73)152 (85)7 (18)130 (84)29 (46)128 (87)5 (16)5 (5) H4 31-50cit145 (67)142 (80)3 (8)119 (77)26 (41)118 (80)2 (6)1 (1) CEP-1140 (65)137 (77)3 (8)117 (76)23 (37)115 (78)1 (3)1 (1) Fil 307-324cit136 (63)134 (75)2 (5)113 (73)23 (37)112 (76)1 (3)0 (0) Fibα 573cit123 (57)121 (68)2 (5)99 (64)24 (38)99 (67)2 (6)0 (0) Fibβ 36-52cit117 (54)116 (65)1 (3)96 (62)21 (33)96 (65)1 (3)2 (2) H3 1-30cit107 (49)106 (60)1 (3)93 (60)14 (22)92 (63)0 (0)0 (0) H4 14-34cit105 (48)103 (58)2 (5)90 (58)15 (24)88 (60)0 (0)3 (3) H3 21-44cit96 (44)94 (53)2 (5)80 (52)16 (25)79 (54)1 (3)1 (1) Fibα 621-635cit93 (43)92 (52)1 (3)78 (51)15 (24)77 (52)0 (0)1 (1) Vim 2-17cit88 (41)87 (49)1 (3)80 (52)8 (13)79 (54)0 (0)0 (0) Fibα 36-50cit79 (36)79 (44)0 (0)67 (44)12 (19)67 (46)0 (0)0 (0) Fibα 591cit69 (32)66 (37)3 (8)56 (36)13 (21)55 (37)2 (6)1 (1) Fibβ 74cit66 (30)60 (34)6 (15)54 (35)12 (19)51 (35)3 (9)3 (3) Fibβ 72cit27 (12)24 (13)3 (8)21 (14)6 (1)20 (14)2 (6)2 (2)*Abbreviations*: *RA* rheumatoid arthritis; *anti-CCP* anti-cyclic citrullinated peptide, *RF* rheumatoid factor, *DAS* Disease Activity Score, *vdHSS* van der Heijde modified Sharp score, *JSN* joint space narrowing, *ACPA* anti-citrullinated protein antibody, *Fib* fibrinogen, *cit* citrullinated, *Vim* vimentin, *H* histone, *CEP-1* citrullinated enolase peptide-1, *Fil* filaggrin; numbers referring to amino acid sequence, *NA* not applicable^a^Mean (SD)^b^Number (percentage)^c^Median \[25, 75 percentile\]Fig. 1Number of anti-citrullinated protein antibody (ACPA) reactivities according to autoantibody status. **a** All patients with rheumatoid arthritis (RA). **b** Controls. **c** Patients with anti-cyclic citrullinated peptide (anti-CCP)+ RA. **d** Patients with anti-CCP- RA. **e** Patients with rheumatoid factor (RF)+ RA. **f** Patients with RF- RA. **g** Patients with anti-CCP+/RF+ RA. **h** Patients with anti-CCP-/RF- RA

ACPA reactivities and disease activity at baseline {#Sec10}
--------------------------------------------------

The DAS, SJC44 and ultrasound grey scale and power Doppler scores were significantly higher in patients who were negative for anti-CCP. Similarly, lack of the most commonly occurring ACPA reactivities (Fibβ 60--74, Vim 60--75 and H4 31--50) was associated with higher DAS, SJC44 and ultrasound grey scale and power Doppler to a statistically significant level (Table [2](#Tab2){ref-type="table"}). When performing the same analyses on the anti-CCP positive cohort only, there were no differences in DAS, SJC44 or ultrasound scores between the patients testing positive versus negative for the ACPA reactivities (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The DAS, SJC44 and ultrasound grey scale and power Doppler scores were negatively correlated with the majority of the ACPA reactivity levels at baseline (Additional file [1](#MOESM1){ref-type="media"}: Table S2). This association was not seen when considering the anti-CCP-positive cohort only (Additional file [1](#MOESM1){ref-type="media"}: Table S3). Number of ACPA reactivities was not correlated with ESR and CRP (data not shown).Table 2Baseline disease characteristics (median values) in anti-CCP and ACPA reactivity-positive versus reactivity-negative patientsESRCRPDASSJC44RAIUS GSUS PDvdHSS EvdHSS JSNvdHSS T*pppppppppp*Anti-CCP+ (82%)210.1070.203.24*\< 0.01*8*\< 0.01*70.1716*\< 0.01*6*\< 0.01*30.7210.1040.37- (18%)1374.09188331431.54.5Fibβ 60--74+ (75%)200.637*0.04*3.28*0.02*7*\< 0.01*70.6517*\< 0.01*6*\< 0.01*30.9710.714.50.73- (25%)19103.87147281130.53.5Vim 60--75+ (73%)180.9570.543.29*0.05*8*\< 0.01*60.8317*\< 0.01*6*0.02*30.9610.264.50.95- (27%)2173.77147239314H4 31--50+ (67%)210.3980.653.27*0.01*8*\< 0.01*6*0.03*17*0.01*6*0.01*30.8810.944.50.70- (33%)1773.84131021930.753.25CEP-1+ (65%)210.1380.933.320.3590.0670.4717*0.03*60.1230.7610.464.50.54- (35%)1763.3611721730.53.5F*il* 307--324+ (63%)210.1580.703.290.067*\< 0.01*70.5417*0.01*6*\< 0.01*30.9410.9840.91- (37%)1773.64137219314Fibα 573+ (57%)220.1380.853.27*0.03*7*\< 0.01*60.1417*0.05*60.1230.6110.234.50.37- (43%)1673.4212821830.54Fibβ 36--52+ (54%)210.0880.783.26*0.05*8*\< 0.01*60.06170.066*0.03*30.581*0.05*4.50.19- (46%)1773.6311819830.53.5H3 1--30+ (49%)180.9770.403.290.4880.0961.0017*0.04*60.0930.620.5*0.04*40.16- (51%)2073.37107197314.5H4 14--34+ (48%)210.1380.743.270.287*\< 0.01*70.77170.3070.8630.3910.3040.28- (52%)1873.45117206314.5H3 21--44+ (44%)220.0990.213.310.6990.0770.84170.2860.4130.680.50.1440.32- (56%)1863.36107197314.5Fibα 621--635+ (43%)220.3680.843.290.097*\< 0.01*70.5416*0.02*60.072.50.460.50.3040.34- (57%)1873.37127207314.5Vim 2--17+ (41%)190.7270.493.290.347*\< 0.01*70.48170.0860.1330.5010.6140.45- (59%)2073.36117207314Fibα 36--50+ (36%)200.7380.863.290.688*0.04*70.46170.086*0.05*30.840.50.2940.59- (64%)1973.41117197314Fibα 591+ (32%)190.7060.293.29*0.05*7*\< 0.01*60.28170.5360.8830.8610.334.50.70- (68%)2083.4011719730.54Fibβ 74+ (30%)220.1980.873.250.5390.1280.74170.0860.672.50.570.50.3240.48- (70%)1873.33107197314Fibβ 72+ (12%)210.2550.593.590.37100.4890.52220.1990.0630.730.50.7240.98- (88%)1973.3197176314Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: *p* values (*p*) were derived from the Mann-Whitney U test; statistically significant differences are in italics*Abbreviations*: *ESR* erythrocyte sedimentation rate (millimetre/hour, 1--140), *CRP* C-reactive protein (milligram/litre), *DAS* Disease Activity Score (0--10), *SJC* swollen joint count (0--44), *RAI* Ritchie articular index (0--78), *US* ultrasound, *GS* grey scale (0--96), *PD* power Doppler (0--96), *vdHSS* van der Heijde modified Sharp score, *E* erosion (0--280), *JSN* joint space narrowing (0--168), *T* total (0--448), *anti-CCP* anti-cyclic citrullinated peptide, *Fib* fibrinogen, *Vim* vimentin, *H* histone, *CEP-1* citrullinated enolase peptide-1, *Fil* filaggrin; numbers referring to amino acid sequence

ACPA reactivities and disease activity after initiation of DMARD treatment {#Sec11}
--------------------------------------------------------------------------

ACPA reactivity levels declined significantly after initiation of DMARD treatment (Fig. [2a](#Fig2){ref-type="fig"}) with the most prominent drop in ACPA reactivity levels occuring within the first 3 months. The delta median change in DAS (after 6, 12 and 24 months), ultrasound grey scale and power Doppler (both after 12 and 24 months) was higher in the ACPA reactivity negative patients, with few exceptions (Table [3](#Tab3){ref-type="table"}). However, these differences between the ACPA reactivity negative versus positive patients in DAS, ultrasound grey scale and power Doppler evened out during follow up (data not shown). The most pronounced relative change comparing baseline levels to levels after 3 months was seen for Fibβ 60--74 and the least marked decrease was for Fil 307--324 (38% vs. 19% decrease, both *p* \< 0.001; Fig. [2a](#Fig2){ref-type="fig"}). We wanted to investigate whether the relative change in ACPA reactivity levels after 3 months differed between patients with lasting methotrexate treatment response and patients requiring triple treatment and/or bDMARDs over the 2 years of follow up. A greater relative change after 3 months of DMARD treatment was seen in most ACPA reactivities in patients who were methotrexate monotherapy responders, and to a statistically significant degree for Vim 60--75 and H4 31--50 (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2Relative change in levels of various anti-citrullinated protein antibody (ACPA) reactivities in patients with early rheumatoid arthritis (RA) (only baseline seropositive patients included) **a** Relative change between baseline and 3, 12 and 24 months, **b** Relative change after 3 months, comparing patients on methotrexate monotherapy at 24 months (*n* = 113) to patients on triple and/or biological disease-modifying antirheumatic drugs (bDMARDs) at 24 months (*n* = 82). Fib, fibrinogen; Vim, vimentin; H, histone; CEP-1, citrullinated enolase peptide-1; Fil, Filaggrin, numbers referring to amino acid sequenceTable 3Change in disease characteristics (delta median values) in ACPA reactivity-positive versus reactivity-negative patientsDelta DAS 6 monthsDelta DAS 12 monthsDelta DAS 24 monthsDelta US GS 12 monthsDelta US GS 24 monthsDelta US PD 12 monthsDelta US PD 24 monthsDelta vdHSS T 12 monthsDelta vdHSS T 24 months*ppppppppp*Fibβ 60--74+−1.9*0.04*−2.0*\< 0.01*− 2. 0*0.02*− 12*\< 0.01*− 13*\< 0.01*−6*\< 0.01*− 6*\< 0.01*0.50.921.00.69--− 2.5−2.6−2.6− 19−21−9−100.51.0Vim 60--75+−1.9*\< 0.01*− 1.9*\< 0.01*− 2.0*0.02*− 12*\< 0.01*− 13*\< 0.01*− 60.06− 6*0.02*0.50.591.00.68--−2.6− 2.6− 2.6−17− 17−8−80.51.0H4 31--50+−1.9*\< 0.01*− 1.9*\< 0.01*−2.0*\< 0.01*− 12*0.05*− 13*\< 0.01*− 60.08− 6*0.02*0.50.151.00.81--−2.5− 2.8− 2.7− 15−17−7−80.51.0CEP-1+−2.00.75− 2.10.79−2.10.48−120.23− 140.24−60.17−60.140.50.501.00.41--−2.1−2.2−2.0−14−14−7− 70.51.0Fil 307--324+−1.9*0.01*−1.8*\< 0.01*− 1.9*0.01*− 120.06− 13*0.01*−6*0.03*−5*0.01*0.50.751.00.76--−2.4−2.5−2.5−16−16−7− 70.51.0Fibα 573+−1.9*\< 0.01*−1.8*\< 0.01*− 1.9*\< 0.01*− 130.36− 140.12−60.21−60.080.50.891.00.77--−2.5−2.6−2.4−13−15−7−70.51.5Fibβ 36--52+−1.9*0.02*−1.9*\< 0.01*− 1.9*\< 0.01*−120.23−140.09−60.08−5*0.02*0.50.891.00.58--−2.4−2.5−2.5−14− 14−7−70.51.5H3 1--30+−2.10.97− 2.20.97− 2.00.44−120.31− 13*0.04*−60.25−60.090.50.241.00.45--−2.0−2.1−2.2−14−16−7−70.51.2H4 14--34+−1.90.07−2.00.12−2.00.14−120.46−12*0.02*−70.63−60.540.50.321.50.10--−2.1−2.3−2.2−14−16−6−60.51.0H3 21--44+−2.00.48−2.00.31−2.00.37−120.29−130.39−60.28−60.380.50.391.50.76--−2.0−2.2−2.2−15−15−7−70.51.0Fibα 621--635+−1.7*0.04*−1.8*0.04*−1.9*0.03*−11*0.02*−13*0.01*−60.09−6*0.05*0.50.201.00.22--−2.3−2.4−2.2−15−16−7−70.51.5Vim 2--17+−1.9*0.04*−1.8*0.02*−1.8*0.01*−120.12−12*\< 0.01*−60.21−5*0.04*0.50.901.00.87--−2.2−2.3−2.3−14−16−7−70.51.0Fibα 36--50+−2.00.83− 2.00.74− 2.00.45−110.09− 120.10−5*0.02*−5*0.02*0.50.611.00.52--−2.0−2.2−2.2−14−15−7−70.51.0Fibα 591+−1.90.08− 1.8*0.03*− 1.8*0.01*− 130.69− 160.70−60.84−60.770.50.411.00.58--−2.2−2.3−2.3−13−14−6−70.51.5Fibβ 74+−1.80.41−2.00.79−2.10.55−120.36−130.94−70.82−70.980.50.061.50.54--−2.1−2.2.−2.0−13−14−6−60.51.0Fibβ 72+−2.00.84−2.00.73−1.90.78− 160.19− 170.21−70.13−90.110.20.980.50.51--−2.0−2.2.−2.1−12−14−6−60.51.0Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: *p* values (*p*) were derived from the Mann-Whitney U test; statistically significant differences are in italics*Abbreviations*: *DAS* Disease Activity Score (0--10), *SJC* swollen joint count (0--44), *US* ultrasound, *GS* grey scale (0--96), *PD* power Doppler 0--96), *vdHSS* van der Heijde modified Sharp score, *T* total (0--448), *Fib* fibrinogen, *Vim* vimentin, *H* histone, *CEP-1* citrullinated enolase peptide-1, *Fil* filaggrin; numbers referring to amino acid sequence

ACPA reactivities at baseline and prediction of treatment response {#Sec12}
------------------------------------------------------------------

There was no difference in median baseline level of the individual ACPA reactivities (data not shown) or baseline median number of ACPA reactivities between patients with successful methotrexate monotherapy according to EULAR good/moderate response and patients with no treatment response after 3 months (9 \[4, 12\] vs. 10 \[4, 11\]; *p* = 0.80). Likewise, no difference was seen in median baseline level of the individual ACPA reactivities (data not shown) or median number of ACPA reactivities in patients reaching remission vs. not reaching remission according to DAS (8 \[3, 12\] vs. 10 \[6, 12\]; *p* = 0.16) or ACR/EULAR Boolean criteria (9 \[4, 12\] vs. 9 \[5, 11\]; *p* = 0.74) after 6 months of methotrexate treatment. Median baseline number of ACPA reactivities for patients reaching vs. not reaching DAS remission at 12 months was 8 \[4, 11\] vs. 10 \[6, 11\], *p* = 0.26 and for 24 months 8 \[4, 12\] vs. 10 \[4, 11\], *p* = 0.87. For ACR EULAR Boolean remission at 12 months, the corresponding numbers were 7 \[3, 11\] vs. 10 \[5, 11\], *p* = 0.08 and at 24 months 8 \[3, 11\] vs. 9 \[6, 12\], *p* = 0.36, respectively.

When stratifying by number of ACPA reactivities, there was a trend that patients with no ACPA reactivities present at baseline were more likely to be in methotrexate monotherapy remission according to DAS after 6 months than patients with 1-5, 6-8or ≥9 ACPA reactivities present at baseline (70% vs. 53%, 53%, and 47%, respectively; *p* = 0.18). No such trend was found for DAS remission at 12 months (81% vs. 67%, 77% and 67%, respectively; *p* = 0.50) or 24 months (89% vs. 85%, 78%, and 78%, respectively; *p* = 0.71). When comparing the proportion of patients in remission according to the ACR/EULAR Boolean remission criteria in relation to number of baseline ACPA reactivities, no trend was seen at 6, 12 or 24 months (data not shown).

ACPA and radiographic damage {#Sec13}
----------------------------

Anti-CCP positivity was not associated with baseline radiographic scores, and neither of the individual ACPA reactivity levels was associated with baseline radiographic scores or baseline erosive disease (Table [2](#Tab2){ref-type="table"}). Overall median observed change in van der Heijde modified Sharp total score after 12 and 24 months did not differ between ACPA reactivity-positive vs. reactivity-negative patients (Table [3](#Tab3){ref-type="table"}). Baseline presence and/or levels of any of the ACPA reactivities were not associated with progression of radiographic damage or change in radiographic score after 12 and 24 months, and seroreversion of any ACPA reactivity after 3 months of treatment was not associated with less radiographic progression after 12 and 24 months (data not shown). Outcomes did not differ when performing subanalyses on the anti-CCP-positive cohort only. Number of ACPA reactivities was not associated with baseline radiographic scores or presence of baseline erosive disease (Table [4](#Tab4){ref-type="table"}). However, there was a trend towards less radiographic progression after 12 and 24 months in patients with no baseline ACPA reactivities compared with 1--5, 6--8 and ≥ 9 reactivities (Fig. [3](#Fig3){ref-type="fig"}), and also when comparing no baseline ACPA reactivities with ≥ 1 reactivities (21% vs. 39% at 12 months, *p* = 0.10 and 33% vs. 39% at 24 months, *p* = 0.66).Table 4Association between number of baseline ACPA reactivities and van der Heijde modified Sharp scores (erosion, joint space narrowing and total) and association between number of baseline ACPA reactivities and baseline erosive diseaseNumber of ACPA reactivities0\
*n* = 271--5\
n = 396--8\
*n* = 37≥ 9\
*n* = 114*p*\
valuevdHSS erosion^a^3.0 \[1.0, 5.8\]3.0 \[1.5, 4.0\]3.0 \[2.0, 4.0\]3.0 \[1.0, 4.5\]0.87vdHSS joint space narrowing^a^1.5 \[0.0, 4.8\]0.5 \[0.0, 2.0\]0.5 \[0.0, 3.0\]1.0 \[0.0, 3.8\]0.54vdHSS total^a^3.0 \[1.5, 11.2\]3.5 \[1.5, 6.0\]4.5 \[2.5, 7.0\]4.2 \[1.5, 9.0\]0.83Erosive disease^b^15 (56)21 (54)21 (57)60 (53)0.97*Abbreviations:* *ACPA* Anti-citrullinated protein antibody, *vdHSS* van der Heijde modified Sharp score^a^Median \[25,75 percentile\]^b^Number (percentage)Fig. 3Proportion of patients with radiographic progression by number of baseline ACPA reactivities after 12 months (*n* = 199) and 24 months (*n* = 195)

Discussion {#Sec14}
==========

To our knowledge, this is the first study to examine the relationship between ACPA reactivities in patients with early RA classified according to the 2010 ACR/EULAR criteria and imaging and serological and clinical disease activity measures, and their potential use in prediction of treatment response and radiographic progression \[[@CR42]\]. The prevalence of ACPA reactivities was associated with anti-CCP/RF positivity, and baseline disease activity measures and ultrasound scores were lower in ACPA reactivity-positive compared to ACPA reactivity-negative patients. ACPA reactivity levels decreased after initiation of DMARD treatment, but the clinical implications of measuring ACPA reactivities to predict treatment response and radiographic progression in this cohort of intensively treated patients with early RA were limited.

High levels of anti-CCP antibodies have previously been shown to be a risk factor for erosive disease \[[@CR1], [@CR2]\], and selected ACPA reactivities have also been shown to be associated with osteoclast activation and radiographic damage \[[@CR23], [@CR24], [@CR26], [@CR27], [@CR43]\]. Kastbom et al. have shown that ACPA reactivity levels declined after 3 months of methotrexate treatment, and that disappearance of certain ACPA reactivities was associated with less 2-year radiographic progression \[[@CR23]\]. In our study, levels of all ACPA reactivities declined after 3 months of DMARD treatment. None of the individual ACPA reactivities analysed were associated with baseline erosive disease or radiographic progression, nor was seroreversion of individual ACPA reactivities associated with less radiographic progression over the 2 years of follow up in our study. Presence, but not titre, of reactivities to citrullinated fibrinogen was associated with faster joint destruction in the ESPOIR cohort of patients with very early RA fulfilling either the 1987 ACR criteria at inclusion or the 2010 ACR/EULAR criteria within 3 years of inclusion \[[@CR26]\]. We identified a trend that patients with ≥ 1 ACPA reactivity at baseline experienced more radiographic progression at 12 and 24 months compared to patients with no ACPA reactivities present, but the findings were not significant. Lack of significant association between number of ACPA reactivities and radiographic progression has previously also been described in the Leiden early arthritis cohort where patients fulfilled the 1987 ACR criteria within 1 year after inclusion \[[@CR29]--[@CR31]\]. Previous studies have not demonstrated association between the individual ACPA reactivities and disease activity measures in early undifferentiated arthritis and early RA \[[@CR29]--[@CR32]\]. ACPA reactivities present in anti-CCP-negative patients with RA have not been shown to be associated with clinical or prognostic parameters \[[@CR22]\]. As previously published, seropositive patients in the ARCTIC cohort had significantly lower disease activity compared to seronegative patients \[[@CR44]\], similar to what has been reported in other cohorts \[[@CR45], [@CR46]\]. The most prevalent ACPA reactivities in our study were negatively correlated with the DAS, SJC44 and ultrasound grey scale and power Doppler scores at baseline, and the disease activity measurements were numerically higher in patients who were negative for the individual ACPA reactivities, which has not been described previously. These differences were no longer present when excluding the anti-CCP-negative subgroup and are thus potentially a consequence of the 2010 ACR/EULAR classification criteria, where the anti-CCP/RF-negative patients require greater joint involvement than the seropositive patients to fulfill the criteria \[[@CR42], [@CR44]\].

Current guidelines for treat-to-target emphasise the importance of improvement in disease activity within 3 months (EULAR good/moderate response) and attainment of the treatment target (ACR/EULAR Boolean remission) within 6 months after initiating treatment \[[@CR47]\]. A greater decrease in ACPA reactivity levels has been demonstrated in treatment responders compared to non-responders \[[@CR23]\]. In our cohort we identified a similar trend whereby reduction in ACPA reactivity levels after 3 months was more pronounced in patients remaining on methotrexate monotherapy after 2 years of follow up, but we did not observe any baseline predictors of treatment response.

Comparison between our results and those of other studies may be limited by the fact that patients in most previous studies were classified by the 1987 ACR criteria or in cohorts of patients treated less intensively. The relatively few anti-CCP-negative patients in comparison with the larger amount of anti-CCP positive patients reflects an effect of implementing the 2010 ACR/EULAR classification criteria \[[@CR33]\] and in this study, the number of patients in the subgroups of anti-CCP and ACPA reactivity-negative patients is somewhat small for meaningful comparisons. When applying the 2010 ACR/EULAR criteria as inclusion criteria, the seronegative patients included in the study were required to have more joint involvement with \> 10 clinically involved joints \[[@CR42]\]. Patients with a clinical seronegative RA diagnosis involving fewer joints were not included. Strengths of the study were that all patients were classified by the 2010 ACR/EULAR criteria, were DMARD and corticosteroid naïve at inclusion and were treated according to a standardised treatment protocol adhering to current treatment recommendations \[[@CR33]\]. The treatment regimen of the ARCTIC trial is well in line with current EULAR recommendations for treatment of early RA \[[@CR47]\]. Such intensive treatment may suppress the RA disease activity to such a degree that prognostic markers identified in previous less strictly controlled RA cohorts may no longer be present or of clinical relevance. The current study was also strengthened by a relatively large sample size and a broad collection of serological, clinical and imaging data.

Conclusions {#Sec15}
===========

New classification criteria and modern intensive treatment strategies have altered the disease course of early RA, and consequently established predictors for treatment response and progression of radiographic damage should be re-evaluated in appropriate cohorts. In this inception cohort of RA patients classified according to the ACR/EULAR 2010 criteria, the prevalence of ACPA reactivities differed in subgroups according to anti-CCP and RF status, and ACPA reactivity levels decreased after initiation of DMARD treatment. There were no apparent associations with disease activity, prediction of treatment response or radiographic progression, and further studies in larger patient samples are needed to understand the role of ACPA reactivities in patients with RA classified according to the 2010 ACR/EULAR criteria.
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Additional file 1:**Table S1.** Disease characteristics (median values) in ACPA reactivity-positive versus reactivity-negative patients in the anti-CCP-positive sub-group (*n* = 178); *p* values were derived from the Mann-Whitney U test and statistically significant differences are marked in bold. Reactivities are sorted by decreasing frequency in the cohort. **Table S2.** Correlation between ACPA reactivities and disease activity (baseline). Spearman correlation (*p* value). **Table S3.** Correlation between reactivities and disease activity in anti-CCP-positive patients (baseline). Spearman correlation (*p* value). (DOCX 41 kb)
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